AdAlta Limited (ASX:1AD)
Australia flag Australia · Delayed Price · Currency is AUD
0.0020
0.00 (0.00%)
Jun 6, 2025, 10:02 AM AEST
-92.59%
Market Cap 2.52M
Revenue (ttm) 973.02K
Net Income (ttm) -4.94M
Shares Out 1.01B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 680,000
Average Volume 1,484,598
Open 0.0030
Previous Close 0.0020
Day's Range 0.0020 - 0.0030
52-Week Range 0.0020 - 0.0290
Beta -0.02
RSI 31.93
Earnings Date May 21, 2025

About AdAlta

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 9
Stock Exchange Australian Securities Exchange
Ticker Symbol 1AD
Full Company Profile

Financial Performance

In 2024, AdAlta's revenue was 1.74 million, a decrease of -49.91% compared to the previous year's 3.47 million. Losses were -5.38 million, 10.9% more than in 2023.

Financial Statements

News

There is no news available yet.